[HTML][HTML] HCC biomarkers–state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice
S Schlosser, D Tümen, B Volz, K Neumeyer… - Frontiers in …, 2022 - frontiersin.org
Hepatocellular carcinoma (HCC) is one of the most common and deadly tumors worldwide.
Management of HCC depends on reliable biomarkers for screening, diagnosis, and …
Management of HCC depends on reliable biomarkers for screening, diagnosis, and …
[HTML][HTML] The advanced development of molecular targeted therapy for hepatocellular carcinoma
T Yan, L Yu, N Zhang, C Peng, G Su… - Cancer Biology & …, 2022 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC), one of the most common malignant tumors in China,
severely threatens the life and health of patients. In recent years, precision medicine, clinical …
severely threatens the life and health of patients. In recent years, precision medicine, clinical …
The interplay of long noncoding RNAs and hepatitis B virus
N Sarfaraz, S Somarowthu… - Journal of Medical …, 2023 - Wiley Online Library
Abstract Hepatitis B Virus (HBV) infections remain a major global health burden with an
estimated 296 million people living with a chronic infection and 884,000 HBV‐related deaths …
estimated 296 million people living with a chronic infection and 884,000 HBV‐related deaths …
A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma
B Pang, Y Leng, X Wang, Y Wang, L Jiang - Annals of Medicine, 2023 - Taylor & Francis
Background Hepatocellular carcinoma lacks ideal diagnostic biomarkers. There is a lack of
scientific evaluation of relevant promising biomarkers as well. Therefore this study …
scientific evaluation of relevant promising biomarkers as well. Therefore this study …
[HTML][HTML] Unique features of hepatitis B virus-related hepatocellular carcinoma in pathogenesis and clinical significance
SH Wang, SH Yeh, PJ Chen - Cancers, 2021 - mdpi.com
Simple Summary Hepatitis B virus (HBV) infection is the major risk factor for hepatocellular
carcinoma (HCC). Understanding the unique features for HBV-induced HCC can shed new …
carcinoma (HCC). Understanding the unique features for HBV-induced HCC can shed new …
[HTML][HTML] Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China
SH Ren, ZL Cui, MR Lang, Q Li, W Zhang… - Journal of …, 2022 - ncbi.nlm.nih.gov
Background Regorafenib is a standard 2nd-line treatment for patients with advanced
hepatocellular carcinoma (HCC), but the efficacy and safety of sequential therapy with …
hepatocellular carcinoma (HCC), but the efficacy and safety of sequential therapy with …
Serum α2, 6-sialylated glycoform of serotransferrin as a glycobiomarker for diagnosis and prediction of clinical severity in cholangiocarcinoma
Background Glycoprotein sialylation changes are associated with severe development of
various cancers. We previously discovered the sialylation of serotransferrin (TF) in …
various cancers. We previously discovered the sialylation of serotransferrin (TF) in …
The index sAGP is valuable for distinguishing atypical hepatocellular carcinoma from atypical benign focal hepatic lesions
QQ Luo, QN Li, D Cai, S Jiang, SS Liu… - Journal of …, 2024 - Taylor & Francis
Purpose The differential diagnosis of atypical hepatocellular carcinoma (aHCC) and atypical
benign focal hepatic lesions (aBFHL) usually depends on pathology. This study aimed to …
benign focal hepatic lesions (aBFHL) usually depends on pathology. This study aimed to …
[HTML][HTML] Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors
X Chen, Z Li, J Zhou, Q Wei, X Wang, R Jiang - PeerJ, 2022 - peerj.com
Methods A total of 216 lung cancer patients from Tianjin Medical University Cancer Institute
& Hospital who received immunotherapy between 2017 and 2021 were included in the …
& Hospital who received immunotherapy between 2017 and 2021 were included in the …
[HTML][HTML] The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma
VT Tran, TT Phan, TB Nguyen, TT Le, TTT Tran… - BMC Research …, 2023 - Springer
Objective This study aims to describe the diagnostic performance of alpha-fetoprotein (AFP),
alpha-fetoprotein L3 isoform (AFP-L3), protein induced by vitamin K absence II (PIVKA-II) …
alpha-fetoprotein L3 isoform (AFP-L3), protein induced by vitamin K absence II (PIVKA-II) …